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Abstract
Recently, there is considerable interest in the field of anti-HIV therapy to identify and develop chromatin-modifying
histone deacetylase (HDAC) inhibitors that can effectively reactivate latent HIV in patients. The hope is that this
would help eliminate cells harboring latent HIV and achieve an eventual cure of the virus. However, how effectively
these drugs can stimulate latent HIVs in quiescent primary CD4 T cells, despite their relevant potencies
demonstrated in cell line models of HIV latency, is not clear. Here, we show that the HDAC inhibitors valproic acid
(VPA) and trichostatin A (TSA) are unable to reactivate HIV in latently infected primary CD4 T cells generated in the
H80 co-culture system. This raises a concern that the drugs inhibiting HDAC function alone might not be sufficient
for stimulating latent HIV in resting CD4 T cells in patients and not achieve any anticipated reduction in the pool
of latent reservoirs.
Background
The presence of resting memory CD4 T lymphocytes
that harbor chromosomally integrated latent HIVs has
been one of the major obstacles in eliminating HIV
from patients using HAART [1,2]. Although the fre-
quencies of these cells in vivo are very low (i.e., ~1-10
latently infected cells per million CD4 T cells), these
highly stable cells serve as a life-long reservoir for HIV
in infected individuals, despite long-term effective ther-
apy [3]. To attain an eventual cure for HIV, if ever
achievable, the elimination of these cells from patients is
necessary, which remains extremely challenging and it is
not clear how that can be achieved.
The mechanisms involved in HIV latency are multifac-
torial [4] and one of the underlying mechanisms found
for the maintenance of latent HIV in transformed cell
lines is the chromatin-mediated suppression of viral
mRNA synthesis from the HIV LTR [5]. The treatment
of latently infected cell lines with HDAC inhibitors,
such as valproic acid (VPA) or trichostatin A (TSA), can
increase the levels of histone acetylation [6,7], leading to
changes in local chromatin organization at the latent
HIV LTR [8-10]. This disruption of compact chromatin
structure at the LTR causes higher levels of HIV
transcription, resulting in the reactivation of latent HIV
[10] and production of viral progeny in cell lines. There-
fore, recent thrusts in the field are to identify potent
HDAC inhibitors and use them clinically, because the
assumption is that once HDAC inhibitors reactivate
latent HIVs in resting CD4 T cells in patients, these
cells will die because of virus-induced cytopathicity and/
or HIV-specific cell-mediated immunity which is pre-
sent. However, it is not entirely clear if these drugs can
stimulate latent HIVs in primary CD4 T cells.
We have previously shown the formation of latent
HIV at high-percentages in HIV-infected primary CD4
T cells in vitro using a feeder cell line, H80 [11], to
keep the lymphocytes alive and healthy. Here, we have
tested whether valproic acid or trichostatin A (both are
HDAC inhibitors) can stimulate HIV in latently infected
primary CD4 T cells generated in our H80 co-culture
system.
Results and Discussion
We generated latently HIV-infected primary T cells as
previously described [11]. Briefly, we started with puri-
fied CD4 T cells from normal donors’ blood. Cells were
stimulated with cross-linked anti-CD3 on plastic dishes
for 2 days. Then the cells were scrapped off and cul-
tured in IL-2 media for 5 days, and were infected with a
frozen stock of a CXCR4-dependent, low cytopathic
HIV strain, MCK, at m.o.i. ~1. The infected cells were
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feeder cell line for 6 weeks as described previously [11].
Typically, ~5-10% of the CD4 cells present are latently
infected by this time point.
T h eTl y m y h o c y t e sf r o mc o - c u l t u r ew e r ec o l l e c t e d
and examined for whether the HDAC inhibitors, VPA
and TSA, could stimulate latent HIV in these primary
cells, given that these compounds are known to reacti-
vate latent HIVs in cell line models of HIV latency by
disrupting suppressive chromatin structures at latent
HIV LTRs. We treated ~0.5 × 10
6 cells with VPA (2
mM) and TSA (150 nM) separately for 18 hours. As a
control for latent HIV stimulation, we also treated these
cells with prostratin (500 nM), a non-tumor promoting
phorbol ester and an activator of protein kinase C. In
our previous study, we found we could reactivate latent
HIV in primary CD4 T cells maintained in H80-cuture
system using prostratin [11]. During these treatment
periods, an HIV inhibitor, AZT, was also added at 0.13
μg/ml concentration to prevent HIV’s spread in culture.
Cells were then stained intracellularly with anti-p24
antibody (Coulter Inc., USA) and analyzed by flow cyto-
metry. As can be seen in Figure 1A, there were about
2.5% of the T cells showing HIV-p24 positivity in mock
(untreated) culture, and ~4-fold increase in the percen-
tage of p24+ cells in culture upon prostratin-treatment
because of reactivation of latent HIVs. However, when
the cells were treated with VPA or TSA, the percentage
of HIV-p24+ cells did not increase over mock
(untreated) culture (Figure 1A), suggesting that VPA or
TSA could not stimulate latent HIVs in these cells. In
contrast, these drugs could effectively stimulate latent
HIV in ACH-2 cells (Figure 1B), a transformed T cell
line having most cells (~90%) latently infected with HIV.
To further assess the stimulatory effects of these drugs
on latent HIVs in primary T cells, we treated these cells
co-cultured on H80 with various concentrations of pros-
tratin, or VPA, or TSA, as indicated in Figure 2. Culture
supernatants were harvested 24 h and 72 h after treat-
ment and then assayed for HIV-p24 levels by using p24
antigen capture EIA (Advanced BioScience Laboratories,
Inc., USA). Similar to the results obtained in flow cyto-
metry, VPA or TSA treatment could not increase the
levels of HIV-p24 in culture supernatants at any time
points or concentrations tested over the levels observed
in mock (untreated) cultures (Figure 2B and 2C),
whereas prostratin-treatment (500 nM or higher) consis-
tently led to relative increases in p24-levels in culture
supernatants by > 2-fold compared to mock (untreated)
control (Figure 2A). These data show that VPA or TSA-
treatment could not cause stimulation of latent HIV in
primary T-cells cultured long-term on H80 feeder cells.
It can be argued that the low-percentages of latently
infected T-cells present in H80 culture system (shown
above) might be a confounding factor for assessing the
responsiveness of latent HIVs to HDAC inhibitors. This
might be because if a minor population among all
latently infected T-cells generated in culture is actually
susceptible to HDAC-inhibitor-mediated reactivation of
latent HIVs, it could have been difficult to detect latent
HIV’s reactivation in our assays. Therefore, we increased
the levels (percentages) of latently infected cells in cul-
ture as follows and then tested them: we infected nor-
mal CD4 T lymyhocytes with HIV-MCK 10-12 days
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Figure 1 Effect of prostratin and HDAC inhibitors on HIV-latency. HIV-infected primary CD4 T cells cultured long-term on H80 (panel A) and
ACH-2 cells (panel B) were treated with prostratin (500 nM), VPA (2 mM) and TSA (150 nM) for 18 hours and % increase in p24+ cells was
determined by intracellular staining with HIV-core antibody (Coulter, USA) followed by flow cytometry as performed previously [11]. Mock
indicates untreated control. One representative experiment out of 5 independent experiments with similar results is shown here.
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Page 2 of 6after stimulation rather than at 5 days after stimulation
as done above or previously [11]. Cells divide at ~5-fold
lower rate at 10-12 days after stimulation than at peak
proliferation phase on day 3 (data not shown). We
found if primary CD4 lymphocytes are infected on day
10-12 after stimulation, much higher percentages of
latently-infected, non-dividing cells are generated after
co-culture on the feeder line, than obtained previously
[11]. In one representative experiment out of 6 indepen-
dent experiments, we found ~18% of the healthy, non-
dividing T cells in long-term cultures were making very
low levels of HIV chronically (Figure 3A). However,
treatment with 500 nM prostratin could increase the
percentages of HIV-p24+ cells to ~31% (Figure 3B),
which was ~1.7-fold increase over untreated controls
(see Table 1). Therefore on average ~15% of cells were
latently infected with HIV in these cultures (Table 1).
Of note, prior to these flow cytometric analyses, these
cells were cultured for 5 days in the presence of AZT at
0.13 μg/ml concentration to prevent the spread of HIV
in culture. Then we treated these cells with VPA or
TSA for 18 hours and stained intracellularly with HIV-
core antibody (Coulter Inc. USA) to compare relative
percentages of HIV-producing cells with or without sti-
mulation. We found in these cultures, also, that VPA or
TSA could not increase the percentages of HIV-p24+
cells (Figure 3, compare panel A with C and D, also see
Table 1), further showing that these HDAC inhibitors
were not effective in reactivating latent HIVs in primary
quiescent T cells generated on H80 feeder cells.
To measure the relative levels of HIV RNA in treated
versus untreated HIV-infected primary T cells, we car-
ried out real-time quantitative RT-PCR for HIV-gag
sequences as follows: total RNA isolated was quantified
using a Nanodrop Spectrophotometer (Nanodrop Tech-
nologies) and qualified by analysis on an RNA Nanochip
using the Agilent 2100 Bioanalyzer (Agilent Technolo-
gies). Synthesis of cDNA was performed with 1 μgo f
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Figure 2 Levels of HIV-p24 in culture supernatants post-stimulation of latent HIV. About 0.5 × 10
6 of long-term cultured HIV-infected CD4
T cells that include latently-infected cells were treated with various concentrations of prostratin (A), VPA (B) and TSA (C) for 72 h. Culture
supernatants were harvested 24 h and 72 h post-treatment and assayed for HIV-p24 levels by using p24-ELISA kit (Advanced Bioscience
Laboratories, Inc., USA). The relative levels of HIV-p24 in various samples were expressed in O.D. values. Only prostratin, at 500 nM or higher
concentrations but not VPA or TSA, could increase the levels of p24 in culture supernatants.
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Page 3 of 6total RNA in a 20 μl reaction volume for 30 min at 48°C
using the reagents in the Taqman Reverse Transcription
Reagents Kit (Applied Biosystems). Real-time quantita-
tive PCR amplifications were performed in triplicates
using 2 μlo fc D N Ai nat o t a lv o l u m eo f2 5μlu s i n g
TaqMan MGB probe with the TaqMan Universal PCR
Master Mix (Applied Biosystems). The final concentra-
tion of the probe was 250 nM and of the primers were
9 0 0n M .B a s e do nt h eH I Vs t r a i n( H I V - M C K )u s e di n
our experiments, the designed probe sequence was 5’-
ACCCCACAAGATTTAAA-3’, and the primer
sequences were: forward, 5’-AATACCCATGTTTT-
CAGCATTATCAGA-3’ and reverse, 5’-TGATGTC
CCCCCACTGT GTT-3’. Relative quantitative RT-PCR
assays were performed with 18S RNA as a normalizer.
All PCR assays were run in the ABI Prism 7000
Sequence Detection System and the conditions were as
follows: initial incubation (50°C for 2 min) and dena-
turation (95°C for 10 min) steps were followed by 40
cycles of amplification (each cycle: 95°C for 15 sec and
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Figure 3 VPA or TSA still remained ineffective on high percentages of latent HIVs in primary T cells. Panel A, High percentages of
latently infected cells were generated on H80 as described in the text and treated with with 500 nM prostratin (B), 2 mM VPA (C) and 150 nM
TSA (D) for 18 hours. The percent increases in p24+ cells were determined by intracellular staining and flow cytometry. Untreated control (Mock)
was shown in panel A. Panel E shows the relative changes in HIV-gag RNA levels after various treatments. The relative levels of intracellular HIV-
gag RNAs were measured by real time quantitative RT-PCR (see text). Prostratin could induce the levels of HIV-gag RNA by 1.7-fold (p < 0.01) in
primary cells, compared to untreated (mock) control, whereas VPA did not induce the level of gag-RNA in these cells. The numbers on top of
each bar indicate fold change relative to untreated (mock) control. Results shown here are from triplicate samples in a representative
experiment. Error bars indicate standard deviations. The statistically significant data (p < 0.01) determined by Student’s t-test is indicated by an
asterisk.
Table 1 Changes in the percentages of p24+ cells in HIV-infected quiescent cultures upon treatment with various
chemicals
Chemicals used to stimulate latent HIVs in
primary T cells
Average % p24+ cells determined by flow
cytometry
Fold-change
in average % p24+ cells in treated vs.
untreated groups
None
(untreated)
18.9 ± 4.3
Prostratin (500 nM) 33.7 ± 4.2 1.78
VPA (2 mM) 18.0 ± 6.2 0.95
TSA (150 nM) 17.1 ± 3.0 0.90
The data were compiled from six independent experiments. ± numbers represent standard deviations.
Sahu and Cloyd Virology Journal 2011, 8:400
http://www.virologyj.com/content/8/1/400
Page 4 of 660°C for 1 min). The analysis showed that prostratin-
treatment could increase HIV-RNA levels by 1.7-fold (p
< 0.01) as shown in Figure 3E, with a concomitant
increase in the percentages of HIV-p24+ cells by ~1.8-
fold (see Table 1). In contrast, HIV-RNA levels in
latently-infected primary T cells remained unchanged
after VPA-treatment (Figure 3E) as did the percentages
of HIV-p24 positive cells (Table 1). These data pre-
sented here demonstrate that latent HIVs in primary
quiescent CD4 T-lymphocytes are not responsive to the
HDAC-inhibitors VPA or TSA.
One of the recent thrusts in the field of HIV treat-
ment focuses on identifying potent HDAC-inhibitors for
use clinically as an adjunct therapy to HAART. This
endeavor stems mainly from previous observation by
Lehrman et. al. [12] who showed the reduction in the
pool of latently infected resting CD4 T cells by ~75% in
3 of 4 patients when treated with VPA in combination
with suppressive HAART. This study, although not defi-
nitive, suggested the possibility that the current antiviral
regimens plus additional drugs targeting latent reser-
voirs may attain cures of HIV in chronically infected
patients. Although subsequent studies by others did not
find similar effects of VPA on latent reservoir in patients
[13,14], these studies opened up new avenues for anti-
viral research aiming to break HIV latency in resting
CD4 T cells in order to achieve depletion of latently
infected cells in patients on HAART. However, our data
demonstrate that VPA or TSA are unable to drive the
expression of virus from its latent state in primary rest-
ing CD4 T cells, in contrast to their well-documented
effectiveness in transformed, actively dividing cell line
models of HIV latency. Our data are also in agreement
with the previous observation by Brooks et. al. [15] who
did not observe reactivation of latent HIV in primary T
c e l l so b t a i n e df r o mt h eS C I D - h u( T h y / L i v )m o u s e
model of HIV-latency.
Although we do not know whether VPA or TSA can
remodel chromatin organization at HIV LTRs in latently
infected primary T lymphocytes generated in our culture
system, the requirements for reactivating latent HIVs
appear multifactorial [4]. For example, resting T cells
possess limiting amounts of various transcription fac-
tors, such as activated nuclear NF-kB, Cyclin T1 and
Cdk9 required for productive transcription to occur
from the HIV LTR [16,17]. There is no evidence indicat-
ing that VPA or TSA-treatment can induce the expres-
sion of these factors in resting primary CD4 T cells or
activate these cells. As a cautionary note, our data pre-
dict that the use of HDAC-inhibitors as adjunct therapy
in the “shock and kill” approach for depleting latent
reservoirs in patients would not be fruitful, unless simul-
taneous activation or induction of expression of cellular
factors (such as NF-kB, CycT1, Cdk9 etc.) essential for
high-level HIV gene expression is achieved in resting
CD4 T cells.
It is worthwhile to mention that during the last dec-
ade, latently infected transformed T cell clones have
been extensively used in the context of mechanistic
studies of the establishment and the maintenance of
HIV latency and its reactivation from the latent state.
However, many of these clones were isolated by
screening and selecting the clones that were responsive
to TNF-a-mediated stimulation of latent HIV con-
structs [18]. Recently Tyagi et. al.[ 1 9 ]h a v eu s e dt h e
H80 system to generate latently infected primary T
cells at high-percentages in vitro using pseudotyped
HIV (negative for its own envelope), and found TNF-a
could not reactivate latent HIVs in these cells. This is
because of restricted cellular levels of P-TEFb (CDK-9,
CycT1) in spite of nuclear NF-kB activation by TNF-a
signaling in these cells [19]. Although we generated
latently infected primary T-cells in the H80 system
using infectious Env+ HIV at lower percentages than
what Tyagi et. al. [19] did; we, likewise, did not
observe activation of latent HIV in these cells upon
TNF-a treatment (data not shown). Altogether, our
and others data obtained from HIV-infected primary T
cells cultured on H80 strongly advocate for studying
HIV latency in non-dividing quiescent normal CD4 T
cells, rather than in transformed, actively dividing cell
lines.
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